<
>
iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. We work passionately to provide precise, powerful healthcare solutions expertly engineered to optimize operational efficiency, clinician confidence and patient outcomes.
We applaud the FDA’s recent announcement of a national dense breast reporting standard.
Ready to standardize your read? Learn more about PowerLook® Density Assessment.
August 16, 2023
Health Canada Grants Device License for iCAD's ProFound Risk 2.0, Revolutionizing Breast Cancer Risk Via a 1-2 Year Assessment
August 14, 2023
iCAD Reports Financial Results for Second Quarter Ended June 30, 2023
July 31, 2023
iCAD to Report Second Quarter 2023 Financial Results on August 14, 2023
July 18, 2023
iCAD Signs Strategic Commercial Agreement with Radiology Partners, the Nation’s Largest Radiology Practice
» View All News »
© iCAD Inc. All rights reserved. iCAD, the iCAD logo, PowerLook, ProFound AI, ProFound, Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.
<
>